Welcome to our dedicated page for Fennec Pharmaceuticals SEC filings (Ticker: FENC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Fennec Pharmaceuticals Inc. (FENC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other documents filed under its Exchange Act reporting obligations. Fennec is a specialty pharmaceutical company focused on PEDMARK®, a sodium thiosulfate injection indicated to reduce the risk of cisplatin-induced ototoxicity in certain pediatric cancer patients.
Recent Form 8-K filings describe material definitive agreements and financing activities, such as an underwriting agreement for an underwritten registered public offering of common shares and subscription agreements for a non-brokered offering of common shares in Canada. These filings outline key terms of the offerings, the number of shares issued, the public offering price and the use of proceeds.
Other 8-K reports detail a Waiver and Redemption Agreement with Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP, under which Fennec agreed to repurchase and redeem its remaining senior secured floating rate convertible notes. The company reports that, after completing this transaction, all payment obligations under the notes were satisfied in full, and related news releases are incorporated by reference in the filings.
On Stock Titan, these filings are updated as they are made available through EDGAR. AI-powered tools can help readers quickly identify the purpose of each filing, such as equity offerings, debt redemptions or other corporate events, and understand how they relate to Fennec’s ongoing commercialization of PEDMARK® and its capital structure. Users can also track exhibits referenced in the 8-Ks, including underwriting agreements, subscription agreements, legal opinions and press releases.
Fennec Pharmaceuticals Inc. (FENC) filed a Form 4 disclosing that Director Rosty Raykov acquired 5,208 common shares on 06/30/2025. The shares were received at $0 cost as they were released from restriction on previously granted awards dated 03/31/2023 and 05/16/2024. Following the vesting event, Raykov’s total direct beneficial ownership increased to 70,670 shares. No derivative securities were exercised or disposed of, and there were no open-market sales associated with this filing.
The transaction is relatively small in absolute terms and represents an internal vesting rather than a cash purchase; however, the absence of sales and the continued accumulation of equity may be read as a signal of ongoing alignment between the director and shareholders.